Understand the source comparison
Comparison: June 2026 High-Impact Peptide Studies
Tirzepatide GIP/GLP-1 dual agonist 23.1% body weight reduction 104 weeks Exceeds single-pathway GLP-1 outcomes by 35–40%; rivals bariatric surgery without invasion Survodutide GLP-1/glucagon dual agonist 18.7% weight loss, 92% lean mass retention 48 weeks Gluc
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Tirzepatide
- GIP/GLP-1 dual agonist
- 23.1% body weight reduction
- 104 weeks
- Exceeds single-pathway GLP-1 outcomes by 35–40%; rivals bariatric surgery without invasion
- Survodutide
- GLP-1/glucagon dual agonist
- 18.7% weight loss, 92% lean mass retention
- 48 weeks
- Glucagon component drives fat oxidation while preserving muscle. Addresses major limitation of weight loss therapies
- Thymalin
- Thymic epithelial signaling
- 34% increase in T-cell production, 28% SASP marker reduction
- 36 weeks
- First documented reversal of age-related thymic involution with immune-senescence biomarkers improving
- Cerebrolysin
- BDNF upregulation via TrkB
- 41% hippocampal neurogenesis increase, 3.2% volume expansion
- 12 weeks
- Structural neuroprotection with functional cognitive improvement. Not symptomatic masking
- Mazdutide
- 16.3% weight reduction, 42% liver fat decrease
- 24 weeks
- Direct hepatic lipid mobilization through glucagon action. Mechanism absent in GLP-1-only compounds